Results 71 to 80 of about 13,037 (207)

Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus [PDF]

, 2014
The pemphigus group comprises the autoimmune intraepidermal blistering diseases classically divided into two major types: pemphigus vulgaris and pemphigus foliaceous.
Adriana Maria Porro, Amagai M, Amagai M, Amagai M, Amagai M, Amagai M, Anhalt GJ, Anhalt GJ, Arranz D, Asahina A, Barrance VP, Beutner EH, Borradori L, Bruckner AL, Bull RH, Buxton RS, Camisa C, Chan LS, Chan LS, Chorzelski TP, Chorzelski TP, Cozzani E, Cunha PR, Czernik A, DeMento FJ, Duarte IB, Durham A, Düker I, Emmerson RW, Fang Y, Feng SY, Fernandes IC, Floden CH, Fullerton SH, Gengoux P, Gooptu C, Gruss C, Hashimoto T, Hashimoto T, Hashimoto T, Hashimoto T, Hashimoto T, Hashimoto T, Hashimoto T, Heng A, Hertl M, Hodak E, Horn TD, Hosoda S, Howell SM, Huff JC, Huhn KM, Iida K, Ingber A, Inui S, Ishii K, Ishii N, Jablonska S, Kaplan I, Kimyai-Asadi A, Kitajima Y, Kopp T, Kowalewski C, Kozlowska A, Kubo A, Kubota Y, Laura de Sena Nogueira Maehara, Lebeau S, Leger S, Leithauser LA, Liu Q, Livia de Vasconcelos Nasser Caetano, Lu Y, Lutz ME, Maciejowska E, Maldonado F, Marinovic B, Martel P, Maruyama H, Marzano AV, Mentink LF, Micali G, Miida H, Milvia Maria dos Santos Enokihara, Mimouni D, Mimouni D, Miura T, Miyagawa S, Miyagawa S, Morita E, Morizane S, Moutran R, Müller R, Nakajima K, Nakashima H, Nguyen VT, Nishikawa T, Nousari HC, Nousari HC, O'Toole EA, Ohata C, Ohyama B, Oiso N, Palleschi GM, Patrício P, Prado R, Qian SX, Robinson ND, Ruiz-Genao DP, Sanchez-Palacios C, Santi CG, Santiago-et-Sánchez-Mateos D, Schepens I, Seah PP, Sklavounou A, Sneddon I, Sneddon IB, Szturz P, Tagami H, Taintor AR, Tajima M, Tateishi C, Tsuruta D, Verdier-Sevrain S, Wakahara M, Wallach D, Wallach D, Wang J, Wang J, Weston WL, Yasuda H, Zaraa I, Zaraa I, Zhu X, Zimmermann J   +134 more
core   +4 more sources

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor [PDF]

, 2003
Drugs that inhibit the epidermal growth factor receptor, such as ZD1839 or C225, are being used increasingly in the treatment of solid tumours. This has led to the appearance of new secondary effects. We describe the case of a patient who
España, A. (Agustín), Fernadez-Galar, M. (Marta), Lopez-Picazo, J.M. (José M.)   +2 more
core   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Síndrome de Reiter exacerbado por indometacina [PDF]

, 1989
A 26-year-old man, with a personal history of drug abuse and positive serology for HIV, had Reiter's syndrome for six years. He experienced progressive worsening of his cutaneous lesions after initiation of indomethacin therapy.
Allegue, F. (F.), Boixeda, P. (Pablo), España, A. (Agustín), Ledo, A. (Antonio), Moreno, R. (R.)   +4 more
core  

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Pustular Psoriasis

, 2018
A number of pustular skin diseases share clinical, pathogenetic, and epidemiological aspects with plaque-type psoriasis, and their classification as a separate clinical entity or as a subtype of psoriasis remains controversial, which is also reflected in the multitude of their names.
Weisenseel, P., Wilsmann-Theis, Dagmar, Kahl, Christoph, Reich, Kristian, Moessner, R.   +4 more
  +5 more sources

Treatment of generalized pustular psoriasis with Spesolimab: a case report and literature review

Pifu-xingbing zhenliaoxue zazhi
Objective To evaluate the efficacy and safety of Spesolimab in the treatment of generalized pustular psoriasis(GPP). Methods A 30 years old female with GPP was intravenously given 900 mg of Spesolimab once.
Xiaoqian LIANG, Zexi MI, Yaohan XU, Yongfeng CHEN   +3 more
doaj   +1 more source

Practical dermatology [PDF]

, 2006
DERMATOLOGYSKIN DISEASESКОЖНЫЕ БОЛЕЗНИМЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИПРАКТИЧЕСКАЯ ДЕРМАТОЛОГИЯRecommendations include tests, clinical tasks and practical skills in dermatology that are used as during practical classes as at the ...
Adaskevich, V. P., Katina, M. A., Valles-Kazlouskaya, V. V.   +2 more
core  

Dermatology 2.0: Precision medicine for inflammatory skin diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio, Antoine Girardin, Curdin Conrad, Teofila Seremet, Michel Gilliet   +4 more
wiley   +1 more source